BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

QuintilesIMS
Chinese Patent Office
Chubb
McKinsey
Boehringer Ingelheim
Citi
Covington
Argus Health
Farmers Insurance
Accenture

Generated: January 18, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 017812

« Back to Dashboard

NDA 017812 describes LITHIUM CARBONATE, which is a drug marketed by Able, Alembic Ltd, Apotex Inc, Glenmark Generics, Hetero Labs Ltd Iii, Mylan Pharms Inc, Usl Pharma, Watson Labs, West-ward Pharms Int, Alembic Pharms Ltd, Barr, Glenmark Pharms Inc, Heritage Pharma, Hikma Intl Pharms, Unique Pharm Labs, Pfizer, and Sun Pharm Inds Inc, and is included in twenty-nine NDAs. It is available from thirty-four suppliers. Additional details are available on the LITHIUM CARBONATE profile page.

The generic ingredient in LITHIUM CARBONATE is lithium carbonate. There are fifteen drug master file entries for this compound. Thirty-five suppliers are listed for this compound. Additional details are available on the lithium carbonate profile page.
Summary for 017812
Tradename:LITHIUM CARBONATE
Applicant:West-ward Pharms Int
Ingredient:lithium carbonate
Patents:0
Therapeutic Class:Bipolar Agents
Formulation / Manufacturing:see details
Pharmacology for NDA: 017812
Medical Subject Heading (MeSH) Categories for 017812
Suppliers and Packaging for NDA: 017812
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
LITHIUM CARBONATE lithium carbonate CAPSULE;ORAL 017812 NDA West-Ward Pharmaceuticals Corp 0054-2526 0054-2526-25 100 CAPSULE, GELATIN COATED in 1 BOTTLE (0054-2526-25)
LITHIUM CARBONATE lithium carbonate CAPSULE;ORAL 017812 NDA West-Ward Pharmaceuticals Corp 0054-2527 0054-2527-25 100 CAPSULE, GELATIN COATED in 1 BOTTLE (0054-2527-25)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrength300MG
Approval Date:Approved Prior to Jan 1, 1982TE:ABRLD:Yes

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrength150MG
Approval Date:Jan 28, 1987TE:ABRLD:Yes

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrength600MG
Approval Date:Jan 28, 1987TE:ABRLD:Yes

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
Teva
Cantor Fitzgerald
Medtronic
Cerilliant
Healthtrust
Deloitte
Farmers Insurance
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot